Atara Biotherapeutics Inc (NAS:ATRA)
$ 0.64 0.035 (5.79%) Market Cap: 77.07 Mil Enterprise Value: 82.84 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Atara Biotherapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 05, 2019 / 12:30PM GMT
Release Date Price: $23.17 (-4.22%)
David Dai
Jefferies LLC - Acting Research Associate

Good morning, everyone. My name is David Dai; I'm the Acting Research Associate here at Jefferies.

It's my pleasure to welcome Utpal Koppikar from Atara; he is the CFO of Atara. We're really excited to hear what his plans are for Atara.

Utpal?

Utpal Koppikar
Atara Biotherapeutics - CFO

Good morning. Thanks, David. I'm Utpal Koppikar, the Chief Financial Officer of Atara. Thanks for giving me the opportunity to tell Atara Bio's story this morning. I'll be making some forward-looking comments, so I direct you to our SEC filings as well as our Web Site if you have any questions.

Great, thank you. So we have quite a few activities going on in Atara. We continue to accelerate Tab-Cel in Phase III for PTLD, post-transplant lymphoproliferative disease. We also are moving forward with our Phase Ib/2 study with Tab-Cel in combination Keytruda in Nasopharyngeal Carcinoma, NPC. Also, we're advancing our next-generation CAR-T mesothelin targeted CAR-T for solid tumors based on some really

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot